Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KJB...
INSV is a true sleeper that is still under the radar of many. When it finally hits the right radars, it is going to make a serious move that I believe will be sustained.
v/r
Sterling
Groundhog day is finally here, smiles all around....
every dog has its day. finally
Stock trading weirdly
Big pop up in ask and giant volume overall today
Wonder what the news is?
robj
thanks,
I'm Ameritrade and their L2 works on most stocks. Just can't get much good on INSV
I use E-TRADE. I don't trade with them but I do use their L2. It's free just need to set up an account.
blackfish, what live site for level 2 do you use?
I'm not very successful on QuoeTracker with INSV
bid list building 4 mm's .40 and above.
Nice to see this stock finally moving. A .42 cent close would be nice. I may have to buy a bit more.
In for few...looks like it's trying to break out. Gotta get past that .41 mark.
Rainmaker, at $.40 I don't think INSV is monetizing DuraSite delivery system very well by concentrating on AzaSite. It's their only focus that i can tell.
Surely there are partners available who have a drug they want delivered by DuraSite?
robj
Rainmaker, at $.40 I don't think INSV is monetizing DuraSite delivery system very well by concentrating on AzaSite. It's their only focus that i can tell.
Surely there are partners available who have a drug they want delivered by DuraSite?
robj
0.40 good to see this after long time
375K+ shares and up 1 cent.
Good-sized and very quiet buying without tripping up the share price.
Who's buying?
100,000 shares in 3 big blocks right at the open for .38. Hopefully somebody's buying for news, eh?
You reckon Inspire is marketing INSV's eye product(s) this flu season. Isn't rubbing your eyes one of the big ways flu spreads?
Gotta have some preventative or treatment connection to H1N1, doesn't it? Does INSV ever pre-announce a good/bad quarter, or is every quarter's revenue a complete surprise? robj
Well, Penny, I'm committed to holding the INSV I've got, but at least I've made some money on BNVI, DARA, DSCO RODM (should have never sold the shares I bought at $1.00 in July--now $5+)
Rainmaker has some good ideas on this one.
I don't see how or really why, INSV would keep going for very long as an independent company.
Big-name partners of B & L and PFE. A bit smaller partner name of Inspire. I'm thinking one of these guys will buy INSV out really soon. I think potential partners see small biotech companies getting bid way up with any FDA announcement. They're seeing cheap prices they might acquire these smaller bios go by the wayside.
I think INSV will be snatched up $1.25-$1.50 before year-end.
I agree. I like INSV but there are too many other biotech opportunities out there to be sitting on this stock forever without any significant movement. It has fluctuated between .35 and .41 cents for the past several months. I've been sitting on 2,000 shares at a .40 cent average since June and I don't what to do.
Rain, INSV sure doesn't act like a biotech, eh? Time for a PR about ISPH or PFE partnering-up with us on something else. too many biotechs exploding to be sitting on INSV too long right now--I'm too stupid to sell, I guess
AzaSite(R) Production Increased in Response to Erythromycin Ophthalmic Ointment Shortage
Monday 09/14/2009 4:03 PM ET - Businesswire
As of 9:58 AM ET 9/15/09
InSite Vision Incorporated (OTCBB: INSV) today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite(R) (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Erythromycin ophthalmic ointment is approved for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery. It is the only product approved for this indication commercially available in the United States. Recently, the U.S. Food and Drug Administration (FDA) placed erythromycin ophthalmic ointment on the FDA's Drug Shortage list. The Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services, the American Academy of Ophthalmology and the FDA all recommend that existing supplies of erythromycin ophthalmic ointment be reserved for the treatment of neonatal prophylaxis use.
These organizations are encouraging healthcare professionals to use alternative drugs, including AzaSite, for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin, as well as for treatment of post-surgical and posttraumatic events. In addition, the CDC has recommended AzaSite as an acceptable substitute for neonatal prophylaxis use where erythromycin ophthalmic ointment is not available. AzaSite has not been approved by the FDA for the treatment of prophylaxis of ophthalmia neonatorum and no clinical trials have been conducted using AzaSite in this population. This recommendation was based on available AzaSite data on pharmacology and gonococcal microbiologic sensitivity. CDC guidance on the erythromycin ophthalmic ointment shortage may be viewed online at: http://www.cdc.gov/std/treatment/2006/erythromycinOintmentShortage.htm
Approved by the FDA in 2007 for the treatment of bacterial conjunctivitis, AzaSite requires the fewest doses per course of treatment of available ocular antibiotic products in the U.S. AzaSite is formulated with InSite Vision's patented DuraSite(R) technology to enhance the retention time of the therapeutic agents on the surface of the eye leading to increased ocular tissue concentrations. InSite Vision and Inspire Pharmaceuticals entered into a licensing agreement for the commercialization of AzaSite in February 2007.
About AzaSite(R)
AzaSite(R) (azithromycin ophthalmic solution) 1% is indicated for the treatment of bacterial conjunctivitis caused by the following organisms: CDC coryneform group G, Staphylococcus aureus, Streptococcus mitis group, Streptococcus pneumoniae, and Haemophilus influenzae.
Important Safety Information: In clinical trials, the most common ocular adverse event was eye irritation, which occurred in 1% to 2% of patients. The safety and effectiveness of AzaSite in pediatric patients below 1 year of age have not been established. The efficacy of AzaSite in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials. Please see full Prescribing Information for AzaSite at www.azasite.com.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. InSite Vision is recognized for the discovery and development of novel ocular pharmaceutical products based on its DuraSite(R) bioadhesive polymer core technology, an innovative platform that extends the duration of drug delivery on the eye's surface, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1% and Besivance(TM) (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and currently marketed by InSite Vision's partner, Inspire Pharmaceuticals in the United States. InSite Vision has formed multiple strategic licensing and distribution agreements with qualified partners to market AzaSite in select countries in Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in the second quarter 2009 and is being marketed by Bausch & Lomb and Pfizer Inc.
InSite Vision's ophthalmic product development pipeline also includes ISV-502 and additional product candidates leveraging the company's core technologies. For further information on InSite Vision, please visit www.insitevision.com.
Forward Looking Statements
This news release contains certain statements of a forward looking nature relating to future events, including , InSite's plans to advance its ophthalmologic products, the implication that AsaSite will be commercialize in various territories outside the U.S. and Canada upon regulatory approval in those territories, and InSite's corporate goals. Such statements entail a number of risks and uncertainties, including but not limited to: the results of any future clinical trials InSite may initiate; InSite's reliance on third parties for the commercialization of its products; the ability of InSite to enter into corporate collaborations for its product candidates; InSite's ability to expand its product platform to include additional indications; InSite's ability to compete effectively, either alone or through its partners, with other companies offering competing products or treatments; InSite's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
SOURCE: InSite Vision Incorporated
InSite Vision
Louis Drapeau, 510-747-1220
Chief Executive Officer
mail@insite.com
or
Availe Communications
Media inquiries
Ellen Rose, 650-387-8746
So, Rain, time for INSV to get out neutral, eh?
That's actually great news for INSV who gets 25% royalty on all AzaSite sales.....very nice find.
Rain, do we get a sniff of Azasite from today's news from Inspire?
http://finance.yahoo.com/news/Inspire-Committed-to-Helping-bw-241028819.html?x=0&.v=1
Rainmaker,
I have been following your DD on INSV and am holding on to my 2K shares until it makes a significant run.
Thanks, Pennystocktrader
The good thing is while we sit and wait, 400 Bausch & Lomb and Pfizer reps are out there everyday selling Besivance which makes INSV and us money. Same for Inspire and their reps....our people have people working for them.
Fair enough, Rain.
Since they have 23 million in cash enough to last them another 2 1/2 years.....I forgive them for being the most boring stock on the planet. The pieces of INSV are worth around $1.50+, trading for .37.....eventually those guys will figure out how to unlock that value and get this trading where it belongs over $1.00. Until then I have no problem leaving my chips on the table here.
Rainmaker? anything about our stagnation surprising to you right now?
someone bought 50K at $.38 (high of day) about 12 minutes before close.
ISPH, some really big insider buys 8.8 million shares+ (Form 4) on our good buddies. Hope INSV is part of the reason for their optimism
Here's a link:
http://www.mffais.com/isph
Nice find thanks for sharing....with this stock one day we'll wake up to news that gaps the stock up over $1.00 before the markets even open. Get in and wait, only way to play this one imho....
INSV is getting ready for a move. I am expecting in next 2-3 weeks TF, we will hear rev projection from BL and Pfizer.
INSV (.37) breakthrough w/big Pharma..This is a key article w/Pfizer & Bausch & Lomb. It was a writeup in the Ocular Surgery News. It speaks to the fact that Pfizer is a key player in the opthalmology space and particularly with Bausch & Lomb. So much so that they are going to be expanding their sales force and putting big money into this opthalmology.
http://www.box.net/shared/emlql6jtxo
"The other major move by Pfizer, announced in March, is a plan to co-promote eye care products with Bausch & Lomb. The 5-year plan essentially doubles the sales force of the two companies while expanding their potential offerings."
Best, Sheff
Saw this on the web.....ISPH
I think the best thing that has happened to INSV in recent weeks is the financing that ISPH secured. This assures the future of INSV, getting more resources behind AzaSite sales Whether we like it or not, INSV's future is tied to ISPH's, and theirs is looking very bright.
I vote my shares for a complete buyout rather than an acquisition. Do they have any other products they are close to licensing or partnering-up on? That could attract a buyer who wants the whole company instead of watching it spread itself out among more PFEs and B & Ls
Besivance is only one of many things INSV has going for it, lot of other news possibilities. We're supposed to get word of what they choose from the Piper Jaffrey Plan this quarter which could involve a merger or acquisition of some type.
Thanks Rainmaker. So it's going to be a long, slow quarter-to-quarter slog while PFE, B & L evaluate the sales of Beiv. lol
Read this somewhere....Besivance? Where's the sizzle?...Let's see..novel anti-biotic not used systemically...novel delivery system..B&L sales effort....PFE sales effort...(they don't get involved unless the product is going to be 100mm)..why else is Pfizer involved unless they plan to buy Bausch & Lomb and then buy back the 6% royalty stream from INSV that is worth about $50-$90 million plus ....what else would you like to know..?
Good find Rainmaker. Plenty of work for the Biev.
Is the only way for the stock price of INSV to increase is for ramping up of sales by our partners? Being in the biotech sector, I'm hoping for more of a homerun from INSV than a slow quarter over quarter slog of partner sales. Where's the flash for the big money here, Rainmaker?
robj
I posted this research report talking about how Besivance Combats MRSA-Besivance effectively kills MRSA and other bactericidal-resistant pathogens.
Research report link: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40913275
Here is a description of MRSA with some stats showing the importance of this topic for potential Besivance sales.
MRSA, or Methicillin-resistant Staphylococcus aureus, is a very serious health threatening microorganisms present in many health care facilities and community environments. MRSA is one of the more serious antibiotic resistant heath threatening microorganisms that contributes to Hospital Acquired Infections (HAI’s). In the U.S. alone, over two million people annually are afflicted with Hospital Acquired Infections with approximately one hundred thousand people dying. Worldwide Hospital Acquired Infections are on the rise and will lead to hundreds of thousands needless deaths annually.
Research report out on Besivance very promising......
Besivance Combats MRSA
Besivance effectively kills MRSA and other bactericidal-resistant pathogens.
Paul M. Karpecki, OD, and Diana L. Shechtman, OD
In 1942, penicillin was first introduced in the U.S. Back then, penicillin was regarded as a “wonder drug” that could eradicate all bacterial infections.1 But, as we know today, many forms of bacteria physiologically mutated and developed resistance to penicillin and other similar antibiotics. In fact, as early as 1960, more than 80% of bacteria found in hospitals developed bactericidal resistance.2
Then, in 1962, naladixic acid––the first quinolone––was introduced. Naladixic acid, and subsequent generations of quinolones, unwound and disrupted the DNA sequence of bacteria, which resulted in a significantly greater kill percentage than penicillin. Today, the fourth-generation fluoroquinolones are able to maliciously disrupt two key enzymes responsible for DNA sequencing of bacteria.3 This specific mode of action likely explains why these drugs demonstrate excellent success against most strains of bactricidal-resistant bacteria.
Besivance demonstrates significant efficacy against MRSA, as seen here.
On May 29, the U.S. Food & Drug Administration approved Besivance (besifloxacin 0.6%, Bausch & Lomb) for the treatment of bacterial conjunctivitis. Besivance, the first “chloro-fluoroquinolone,” has demonstrated tremendous success in the elimination of common ocular pathogens, including methicillin-resistant Staphylococcus aureus, in preliminary microbiological studies.4 Here, we provide a brief review of bactericidal resistance and explain how Besivance will play a role in your therapeutic armamentarium.
Bactericidal Resistance
According to the Ocular Tracking Resistance in the United States Today (TRUST) study, 70% of the bacteria isolated in hospitals are resistant to at least one conventional antibiotic.5 And, what’s just as alarming: The study also revealed that more than half the Staphylococcus aureus isolates sent to the TRUST laboratory between 2006 and 2007 were methicillin resistant.
Bactericidal resistance is a result of many factors, including over-prescription of antibiotics, negligent prescription of antibiotics (e.g., wrongly prescribing antibiotics for a viral condition) and improper dosing of antibiotics (including patient noncompliance).7
But, perhaps the most significant cause of bactericidal resistance is the widespread use of antibiotics in agriculture. For example, commercial farmers frequently blend antibiotics into animal feed to prevent livestock illness.8 This sort of imprudent antibiotic use has contributed to bacterial mutation and bactericidal resistance.9
An Introduction to Besivance
As previously mentioned, both third- and fourth-generation fluoroquinolones disrupt the action of two enzymes that are chiefly responsible for bacterial DNA replication.3 However, the unique C-8 chlorine component of the besifloxacin molecule provides enhanced inhibition of these two key enzymes.4 Additionally, its C-7 amino-azepinyl component is thought to contribute to broad-spectrum activity against gram-positive organisms.4
Also unique, Besivance is only available as an ophthalmic suspension. It is formulated in the DuraSite vehicle (InSite Vision Inc.), which prolongs the drug’s contact time on the ocular surface. Currently, there are no plans to create a systemic version of Besivance.
Current Data
One study suggested that besifloxacin’s potency against DNA gyrase and topoisomerase IV associated with in vitro cases of Streptococcus pneumoniae and Staphylococcus aureus was equal to that of previous fluoroquinolones, even at lower concentrations.10 Also, this study documented no resistant bacterial mutations in the presence of besifloxacin.
Another recent study suggested that besifloxacin exhibited significant anti-inflammatory properties on both in vitro and in vivo primary human corneal epithelial cells.11 And, one additional study showed that besifloxacin inhibited inflammation in 14 different cytokines and/or inflammatory mediators, which illustrated its potential utility against ocular infection.12
Besivance and Resistance
Besivance demonstrates significant effectiveness against MRSA and other bactericidal-resistant pathogens. One in vitro study of 2,690 clinical isolates from 40 species of bacteria showed that the minimum inhibitory concentrations for besifloxacin were at least two to four times lower than the other antibiotics tested.13 Most notably, besifloxacin proved effective against gram-positive pathogens and anaerobes as well as both gram-positive and gram-negative bacterial isolates deemed widely resistant to fluoroquinolones, including MRSA.13
Because of bacteria’s ability to mutate and form bactericidal-resistant strains, there is a consistent demand for more effective agents. Fortunately, cutting-edge drugs, such as Besivance, will give clinicians the upper hand in the treatment and prevention of infectious ocular disease.
Dr. Karpecki is a consultant to Bausch & Lomb. Neither he nor Dr. Shechtman has any direct financial interest in any of the products mentioned.
1. Domin MA. Highly virulent pathogens in a post-antibiotic era? Br J Theatre Nurse. 1998 May;8(2):14-8.
2. Kirby WM, Bulger RJ. The new penicillins and cephalosporins. Annual Rev Med. 1964;15:393-412.
3. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S120-6.
4. Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocular Pharmacol Ther. 2007 Jun;23(3):243-56.
5. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008 Jun;145(6):951-58.
6. Cuvuoto K, Zutshi D, Karp CL. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008 Jan;115 (1):51-6.
7. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control. 2006 Jun;34(5 Suppl 1):S38-45; discussion S64-73.
8. Piddock LJ. Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance. BMJ. 1998 Oct 17:317(7165):1029-30.
9. Chee-Sanford JC, Mackie RI, Koike S, et al. Fate and transport of antibiotic residues and antibiotic resistance genes following land application of manure waste. J Environ Qual. 2009 Apr 27;38(3):1086-108. Print 2009 May-Jun.
10. Cambau E. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumonia, Staphylococcus aureus and E. coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50.
11. Zhang JZ, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res. 2008 Nov;33(11):923-32.
12. Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocyctes. J Antimicrob Chemother. 2008 Jan;61(1):111-6.
13. Haas W. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic anaerobic bacteria. Antimicrob Agents Chemother. 2009 Aug;53(8):3552-60.
Vol. No: 146:08Issue: 8/15/2009
http://www.ocularnutritionatoz.com/
http://www.retinarevealed.com/
I believe it was NITE on the bid.
Pushin .4's with NITE on the bid and ask. I think I know who will get this one..
okay, Rainmaker, good on Durasite.
How much does it cost the company and how is it paid for, would you expect?
Someone else doesn't have DuraSite a technology which allows the medication to remain on the eye twice as long. It's not the drug itself, it's the DuraSite technology that gives INSV the edge imho.
Rainmaker, here's Bromfenac.
If it's really a hot property, won't a bigger company than INSV want it and quickly price us out.
How much will it cost the company and how will it be paid for--please not share dilution
If all this stuff you hear is true, you are some plugged in dude here.
robj
Not sure who knows how to research this but here's a source of some serious potential buzz for INSV. There is a drug called Xibrom(Bromfenac). The rumor is that this drugs patent protection is about to expire soon. INSV CEO has some serious plans ready to go for this.... INSV will then be able to combine DuraSite with it and Insite could control a large chunk of Xibrom(Bromfenac) market. Remember the whole key for INSV is that InSite’s DuraSite technology is designed to achieve increased retention time of the therapeutic agents on the surface of the eye relative to conventional topical therapies that are rapidly rinsed away by tears. Pretty sure Xibrom(Bromfenac) is prescribed for patients coming off cataract surgery.
Xibrom™ Overview:
Xibrom™ ophthalmic solution is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. For more details, including prescribing info , click here . The product was developed by Senju in Japan. Senju launched Xibrom in Japan with the tradename Bronuck® in 2000. We believe its rapid sales growth is principally due to its potency and twice-daily dosing regimen, as compared to the requirement of four doses-per-day for most other anti-inflammatory products on the Japanese market. In May 2002, as part of our AcSentient asset acquisition, we acquired marketing rights for Xibrom™ in the United States.
How Xibrom™ Works (Mechanism of Action):
Xibrom™ is a member of the class of non-steroidal anti-inflammatory drugs (NSAIDS). These are aspirin-like drugs that are inhibitors of prostaglandins. These are a group of compounds that act in tissues where they are liberated to elicit various inflammatory activities. Prostaglandins are generated in most tissues by activation of the arachidonic acid pathway. Briefly, phospholipids in the cell membrane are the substrate for the enzyme phospholipase A to cause generation of arachidonic acid and, in turn, the enzymes cyclo-oxygenases and lipoxygenases act on arachidonic acid to produce a family of chemically distinct prostaglandins (cyclo-oxygenases), and leukotrienes (lipoxygenases).
Xibrom™, like other NSAIDS, acts primarily to inhibit cyclo-oxygenases and prevents the formation of prostaglandins. This subsequently decreases the inflammation in the site of action following drug penetration. Thus, Xibrom™ treatment of eyes with inflammation following cataract surgery may stop the formation of prostaglandin and halt the inflammatory response to surgical trauma.
Xibrom™ Market Opportunity:
According to prescription data compiled for us by IMS Health, we estimate that the current U.S. ophthalmic anti-inflammatory market to be approximately $250 million per year. Currently in the U.S., we estimate that there are over 5.4 million prescriptions written annually for topical ophthalmic anti-inflammatory agents. The topical ophthalmic anti-inflammatory market consists of steroids, NSAIDs and combination products. Based upon 2005 prescription data from IMS, ISTA estimates that U.S. sales in 2005 in this market were approximately $400 million, with total prescriptions of 8.8 million.
Grabbed a few more this morning and I'm still sitting at .37 for more .......
Filled Buy 3500 INSV Limit 0.37 -- -- 09:30:12 08/25/09
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
346
|
Created
|
06/03/09
|
Type
|
Free
|
Moderators |
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. Our mission is to develop and facilitate market entry for novel products worldwide that preserve and improve vision.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, is approved by the United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis. AzaSite is formulated with our proprietary DuraSite® technology, which extends the residence time of the antibiotic azithromycin on the eye for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals, InSite’s commercial partner for the U.S. and Canada and will be marketed by international partners in Japan, Europe, South Korea, select countries in South America, Turkey and China upon approval in those countries. InSite will also pursue partnerships with companies who share our commitment to bringing innovative ophthalmic products such as AzaSite to patients worldwide.
AzaSite Plus (ISV-502), another product candidate in the AzaSite family, is currently in late-stage development for the treatment of eyelid infection and inflammation, specifically for the indication of blepharitis.
Our strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for our DuraSite-enabled early-stage product candidates, and applying our expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.
http://www.insitevision.com/partners
Commercial partnerships: InSite Vision receives royalty payments from our two commercial products, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and marketed by InSite Vision’s partner, Inspire Pharmaceuticals. InSite Vision has also formed multiple strategic licensing and distribution agreements with partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in 2009 and is being commercialized by Bausch & Lomb and Pfizer Inc. We work closely with our partners to support and extend product sales.
http://www.insitevision.com/product_pipeline
Phase Chart
Authorized Shares (AS) = 240 million
Outstanding Shares (OS) = 94.74 million
Restricted Shares = 21.73 million
Float = 73.01 million
http://finance.yahoo.com/q/ks?s=INSV.OB
INSV News
http://finance.yahoo.com/q/h?s=INSV.OB
INSV SEC Filings
http://finance.yahoo.com/q/sec?s=INSV.OB
INSV Management
· Louis Drapeau
Chief Executive Officer, Vice President and Chief Financial Officer
· Lyle M. Bowman, Ph.D.
Vice President, Development
· David Heniges
Vice President and General Manager, Commercial Opportunities
· Kamran Hosseini, M.D., Ph.D.
Vice President, Clinical Affairs and Chief Medical Officer
· Surendra Patel
Vice President, Operations and Quality
INSV Contact Information
http://finance.yahoo.com/q/pr?s=INSV.OB
Insite Vision Inc.
965 Atlantic Avenue
Alameda, CA 94501
United States - Map
Phone: 510-865-8800
Fax: 510-865-5700
Web Site: http://www.insitevision.com
Daily View
Weekly View
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |